Regulatory Considerations for Genome-Edited T-cell Therapies

Keyphrases

• T Cells 100%
• Adoptive Cell Therapy 100%
• Regulatory Approval 100%
• Gene Therapy 50%
• Therapeutic Intervention 50%
• Cell Therapy 50%
• Biological Function 50%
• Human Cells 50%
• Chimeric Antigen Receptor T Cells (CAR-T) 50%
• Precision Medicine 50%
• Endogenous Genes 50%
• Genome Editing 50%
• Therapeutic Efficacy 50%
• Gene Therapy Vectors 50%
• Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) 50%
• Regulatory Oversight 50%
• Cellular Products 50%
• Gene-edited 50%
• Chimeric Antigen 50%

Medicine and Dentistry

• T Cell 100%
• Gene Therapy 100%
• Cell Therapy 100%
• T Lymphocyte 50%
• Combination Therapy 50%
• Transgene 50%
• Personalized Medicine 50%
• Clustered Regularly Interspaced Short Palindromic Repeat 50%
• Biological Functions 50%
• Genome Editing 50%
• Chimeric Antigen Receptor 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Combination Therapy 100%
• Chimeric Antigen Receptor 100%